Analyst Price Target is $8.00
▲ +183.69% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ImmunoPrecise Antibodies in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 183.69% upside from the last price of $2.82.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in ImmunoPrecise Antibodies. This rating has held steady since October 2021, when it changed from a Hold consensus rating.
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.